News
BXPHF
0.031
NaN%
--
Botanix Seeks ASX Quotation for 3.6 Million New Shares
TipRanks · 2d ago
Botanix Wins Shareholder Backing for A$45m Capital Raising to Fund Sofdra Rollout
TipRanks · 04/01 05:31
Botanix Defers API Purchases and Moves to De-Risk Sofdra Supply Chain
TipRanks · 03/29 22:28
Botanix Showcases FDA-Approved Hyperhidrosis Drug at Euroz Hartleys Conference
TipRanks · 03/17 23:10
Botanix to Lift Voluntary Escrow on 3.1 Million Shares
TipRanks · 03/13 01:17
Botanix Revises Securities Purchase Plan Timetable and Sets Approval Date
TipRanks · 03/10 23:38
Botanix updates timetable for share purchase plan securities issue
TipRanks · 03/10 23:28
Botanix Opens Underwritten Security Purchase Plan to Fund Dermatology Growth
TipRanks · 03/10 23:28
Botanix launches underwritten SPP and option offers tied to shareholder approval
TipRanks · 03/10 22:19
Botanix Pharmaceuticals price target lowered to A$1 from A$2 at H.C. Wainwright
TipRanks · 03/04 11:12
Botanix Pharmaceuticals’ Sofdra Drives Growth Amid Cash Strain
TipRanks · 03/04 00:10
Botanix outlines limits and risks in 2026 half-year investor briefing
TipRanks · 03/02 23:36
Botanix flags solvency risk as April vote decides fate of capital raising
TipRanks · 03/01 23:11
Botanix Wins ASX Waiver to Enable Shareholder Vote on Capital Raising
TipRanks · 03/01 22:45
Botanix corrects prior-period revenue typo as half-year sales surge but losses widen
TipRanks · 03/01 22:43
Botanix revenue surges but losses deepen and asset base thins
TipRanks · 02/27 04:38
Botanix Opens Investor Webinar Registration as Sofdra Launch Advances
TipRanks · 02/26 00:45
Botanix Raises A$14.9m in First Tranche of A$40m Placement
TipRanks · 02/23 23:53
Botanix Seeks ASX Quotation for 248 Million New Shares
TipRanks · 02/23 04:32
Sofdra’s Strong Early Launch, High Refill Momentum, and Expanding Market Support Buy Rating on Botanix Pharmaceuticals
TipRanks · 01/28 14:55
More
Webull provides a variety of real-time BXPHF stock news. You can receive the latest news about Botanix Pharma through multiple platforms. This information may help you make smarter investment decisions.
About BXPHF
Botanix Pharmaceuticals Limited is an Australia-based dermatology company. The Company’s lead product is Sofdra (sofpironium) topical gel, 12.45%, a prescription anticholinergic medicine used on the skin (topical), to treat excessive underarm sweating (primary axillary hyperhidrosis) in adults and children nine years of age and older. Sofdra regulates sweating at the site of application, by binding to the primary sweat receptor and thereby blocking the sweat signal. Its product pipeline targets the various skin diseases, such as BTX 1503 for Acne, BTX 1702 for Rosacea, BTX 1204A for Atopic Dermatitis, and BTX 1801 for Hemodialysis Patients. Its BTX 1503 is a transdermal gel formulation for the treatment of serious acne in adults and teenagers. BTX 1702 is used for the treatment of papulopustular rosacea. BTX 1801 is an antimicrobial gel focused on targeting Staphylococcus Aureus and Methicillin Resistant Staphylococcus Aureus (MRSA).